Strategic Insights & Growth Support / Service
Analysis of FDA Complete Response Letters to surface recurring deficiencies, review-division expectations, approval barriers, and resubmission risk — translating agency precedent into decisions companies can act on.
The Work
Complete Response Letters are one of the most underused signals in FDA strategy. They tell you, in the agency's own language, what a specific review division actually objected to, what evidence it found insufficient, and what kept a product from approval. Yet most companies only look at CRLs reactively — when one lands on their own program — rather than mining precedent before commitments are made.
CRL Compass™ reverses that posture. RGM analyzes the public CRL record across an indication, a review division, or a product class, and surfaces the patterns that matter: recurring deficiency categories, the kinds of evidence that have failed before, the questions a specific division keeps coming back to, and the conditions under which resubmissions have succeeded or stalled. The work translates raw agency precedent into a decision-ready read on what the FDA is most likely to push back on next.
The applications are practical. In pathway selection, CRL Compass informs whether a chosen route has a track record of approvals or a track record of rejections. In pre-submission planning, it surfaces the deficiencies most likely to surface again, allowing the development plan to address them before they become a complete response. In resubmission planning after an actual CRL, it provides context for which deficiency types tend to be successfully resolved and which signal a deeper structural issue. And in investor diligence on a development-stage company, it gives a board or investment committee a precedent-based view of the regulatory risk the program is actually carrying.
Companies typically engage RGM here when they are entering pre-submission planning for a regulated program, responding to an actual CRL, supporting investor diligence on a clinical-stage asset, making a pathway-selection decision in a regulated category, or doing strategic planning before committing significant resources to a development program.
A written precedent analysis with citations to the underlying CRLs. A risk-by-deficiency-category map. A decision-ready summary for executive or board audiences. And specific recommendations for pre-submission de-risking or resubmission strategy — tied directly to what the agency has previously said, not to what it might.
More in This Pillar
